Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732069 · ClinicalTrials.gov registry record · Phase 2
Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00732069: Completed Phase 2 study, sponsored by Vanderbilt University.
NCT00732069 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00732069, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Little is known about how some drugs affect inflammation or clotting factors in people receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they do in people not undergoing hemodialysis or whether they could increase the risk of heart problems. The purpose of the study is to measure certain chemicals in the blood and see how those chemicals may change during hemodialysis when certain drugs are given.
Primary Outcome
Mean difference in interleukin 1 beta concentration during treatment with ramipril versus treatment with placebo
Interventions
- DRUG Placebo
- DRUG Ramipril
- DRUG Valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00732069 record still lists
NCT00732069 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00732069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00732069 about?
NCT00732069 is a clinical study titled "Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis". Little is known about how some drugs affect inflammation or clotting factors in people receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they do in people not undergoing hemodialysis or whether they could increase the risk of heart problems. The purpose of the s...
What is the current status of trial NCT00732069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2008-08. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00732069?
The interventions under investigation include: Placebo (DRUG), Ramipril (DRUG), Valsartan (DRUG).
Who is sponsoring clinical trial NCT00732069?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00732069's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia